Our findings promote the use of the cumulative APD/mid-parenchymal thickness ratio combined with β2-M and uNGAL in the workup of borderline cases and justify further quantitative proteome analysis and biomarker studies developing biomarker kits for non-invasive obstructive uropathy diagnosis (14–17). Here, B2M is linked to urinary tract obstruction.